Industry News_News Center_FUSEN PHARMACEUTICAL

Fusen Shuanghuanglian Oral Liquid has been listed as a "Chinese Family Regular Drug Brand"!

05 2023.12

Fusen News | [Translated from: Hengqin Online] Sichuan Australia Joins Hands, Traditional Chinese Medicine Innovation Project Landing in Hengqin!

19 2023.06

At the 86th Drug Fair, we are a strong fan of Fusen Pharmaceutical!

24 2023.05

Good news! Fusen Pharmaceutical Co., Ltd. was listed as the "top 100 Chinese patent medicine enterprises in 2021"

27 2021.12

[Chinese Medicine List] "2021 China Chinese Medicine R&D Strength Ranking TOP50" is grandly released!

In recent years, the state has vigorously supported and promoted the development of Chinese medicine, put the development of Chinese medicine in a prominent position, made many decisions and deployments, and issued supporting policies for the Chinese medicine science and technology industry. "Guiding Opinions on the Integrated Development of Chinese Medicine Health Services and the Internet" and the "Traditional Chinese Medicine Law" guide the development of the Chinese medicine industry to 2020. The "Administrative Measures for Drug Registration" and "Registration Classification and Application Information Requirements for Chinese Medicines" put forward new requirements for the research and development of new Chinese medicines. All have pointed out the direction for the inheritance and innovation of traditional Chinese medicine, and promoted "the revitalization and development of traditional Chinese medicine usher in a great opportunity for the right time, the right place, and the harmony of people." In addition, as the aging population increases, people’s health awareness of prevention is better than cure, prevention before disease and prevention of changes in existing diseases. Traditional Chinese medicine with the unique advantages of "preventing diseases" will usher in a good opportunity for development, especially in 2020. The indispensable and important role of Chinese medicine in the prevention and treatment of major diseases demonstrated in the fight against the new crown epidemic has brought new development opportunities for the research and development of new Chinese medicines, and also ushered in opportunities for the revitalization of the development of Chinese medicine and the international development. In fact, discovering the treasures of the motherland’s medicine, inheriting the essence of innovative Chinese medicine, promoting the R&D and industrial development of Chinese medicine with technological innovation, and developing “effective and high-quality” new Chinese medicines. Pharmaceutical companies regard it as an important mission to achieve their own innovation and upgrade, enhance core competitiveness, and revitalize the development of traditional Chinese medicine. On September 18, 2021, the "2021 High-Quality Development Conference of the Big Health Industry and the Sixth China Pharmaceutical Research and Development Innovation Summit (PDI)" released the "2021 China TCM R&D Strength Ranking List TOP50" (hereinafter referred to as the "Chinese Medicine List"" ), 50 leading Chinese medicine innovation frontiers.

24 2021.09

[Chinese Medicine List] "2021 China Chinese Medicine R&D Strength Ranking TOP50" is grandly released!

Facing the future, Fussen Pharmaceutical Co., Ltd. is striving to revitalize national medicine as its mission

Henan Fusen Pharmaceutical Co., Ltd. was listed on the main board of the Hong Kong Stock Exchange in 2018 with stock code: 1652.HK. It is a modern comprehensive pharmaceutical company integrating medicinal plant cultivation, drug research and development, production and operation. Since its establishment in 2003, the company has been adhering to the concept of "honesty and trustworthiness, solid foundation, brand wins, and steady development", adheres to the road of "quality, technology and talents", and constantly improves the industrial chain and optimizes Internal and external resources, successively controlled the pharmaceutical research and development company Beijing Sanye Mingming Pharmaceutical Technology Co., Ltd. and the pharmaceutical distribution company Jiangxi Yongfeng Kangde Pharmaceutical Co., Ltd., and formed strategic alliances with China Resources Pharmaceutical Business Group and Jointown Pharmaceutical Group to form production, research and development, The three major areas of sales have a good development trend of "troika and synergy". It has successively won the titles of the National "Agricultural Industrialization Leading Enterprise" and Henan Province "Excellent Private Enterprise", "High-tech Enterprise", "Hundred High Enterprise" and Nanyang City's Backbone Enterprise and Top Ten Enterprise. Ingenuity quality, perfection. The company has always adhered to the pharmaceutical concept of "survive by quality". With the help of the rich resources of Chinese medicinal materials in the Funiu Mountain of 800 miles and the advantages of the first-class water quality resources in the Danjiang Reservoir of the South-to-North Water Diversion, the company has established a GAP planting base for Chinese medicinal materials to ensure product quality from the source. In strict accordance with the requirements of the national GMP production standards, we continuously optimize the production process, strictly control the process, and use ingenuity to cast drugs that "make people feel at ease". The company's existing product treatment areas cover heat-clearing and detoxifying products, cardiovascular and cerebrovascular products, blood pressure and blood sugar reduction, tonic, qi regulation, anti-anemia, antibacterial and anti-inflammatory products, among which heat-clearing products Shuanghuanglian Oral Liquid, Shuanghuanglian Injection The sales volume of liquid sheet products ranks among the top three of similar products in the country for many consecutive years. They are "National Conformity Assessment and Quality Reliable Products" and "High Quality Products in Henan Province"; Cardiovascular and cerebrovascular products, Flunarizine Hydrochloride Capsules, are the first imitation products in the country. , Ranking first in the domestic sales of similar products for five consecutive years; three exclusive varieties of Qi-regulating products Yuanhu Zhitong Oral Liquid, Ganweikang Tablets and Cardio-Cerebrovascular Products Yixinkang Tablets have been included in the national protection of traditional Chinese medicine. Technology is the foundation, innovation is the soul. The company always stands at the forefront of medical technology, adheres to the innovative development strategy, implements the policy of "integration of Chinese and Western, combination of long and short, and combination of imitation and innovation", and takes the road of new drug development of "generation of production, generation of reserves, generation of research and innovation", and research and development Innovation is the strategic basis for the high-quality development of the company. Fussen (Shenzhen) Biomedical R&D Co., Ltd. and Fussen (Macau) Co., Ltd. have been established successively, as R&D centers in the field of improved and innovative drugs, and continue to strengthen R&D capabilities and broaden product portfolios. To create a "health industry group integrating medicine, chemical medicine and biopharmaceuticals". Under the background of healthy China, the company will adhere to the corporate philosophy of "ingenuity quality • health is a blessing", taking science and technology as the forerunner, based on the traditional Chinese medicine industry, absorbing modern technology, and casting a healthy character, determined to create a century-old Fussen, a century-old brand, and Contribute to the development of the national pharmaceutical industry.

26 2021.08

Facing the future, Fussen Pharmaceutical Co., Ltd. is striving to revitalize national medicine as its mission